Molecular Targets for the Treatment of Juvenile Myelomonocytic Leukemia

• Type of Material: Article
• Authors: Xiaoling Liu, Case Western Reserve University; Himalee Sabnis, Emory University; Kevin Bunting, Emory University; Cheng-Kui Qu, Case Western Reserve University
• Language: English
• Date: 2011-08-11
• Publisher: Hindawi Publishing Corporation
• Publication Version: Final Published Version
• Copyright Statement: © 2012 Xiaoling Liu et al.
• License: Creative Commons Attribution 3.0 Unported
• Final Published Version (URL): http://www.hindawi.com/journals/ah/2012/308252/
• Title of Journal or Parent Work: Advances in Hematology
• ISSN: 1687-9104
• Volume: 2012
• Issue: 2012
• Start Page: 1
• End Page: 7
• Grant/Funding Information: This work was supported by the National Institutes of Health Grants HL068212 and HL095657 (to C.-K. Q.), DK059380 (to K. D. Bunting), Cure Childhood Cancer Foundation (to K. D. Bunting and H. Sabnis), Rally Foundation for Childhood Cancer Research (to K. D. Bunting), and the Case Comprehensive Cancer Center Cancer Stem Cell Pilot Grant (to C.-K. Qu).
• Research Categories: Health Sciences, Oncology; Health Sciences, Medicine and Surgery; Engineering, Biomedical

Abstract

Significant advances in our understanding of the genetic defects and the pathogenesis of juvenile myelomonocytic leukemia (JMML) have been achieved in the last several years. The information gathered tremendously helps us in designing molecular targeted therapies for this otherwise fatal disease. Various approaches are being investigated to target defective pathways/molecules in this disease. However, effective therapy is still lacking. Development of specific target-based drugs for JMML remains a big challenge and represents a promising direction in this field.